Amgen study shows cardiovascular health benefits of Repatha

Amgen has announced new clinical trial data showing the positive cardiovascular health benefits of its cholesterol-lowering therapy Repatha.

Data from the FOURIER study has indicated that Repatha was able to reduce the risk of cardiovascular events in patients with clinically evident atherosclerotic cardiovascular disease.

The drug met its primary endpoint by cutting patients' risk of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, hospitalisation for unstable angina or coronary revascularisation. It was also shown to be non-inferior to placebo in terms of its effect on cognitive function.

This comes after a previous study indicated that Repatha has a positive effect in addressing atherosclerosis, the underlying cause of cardiovascular disease. 

Dr Sean Harper, executive vice-president of research and development at Amgen, said: "These FOURIER results show unequivocally the connection between lowering LDL cholesterol with Repatha and cardiovascular risk reduction, even in a population already treated with optimised statin therapy."

Repatha is approved in more than 40 countries, including the US, Japan, Canada and the 28 EU nations.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.